Menu
← Oncology Approval Tracker
FDA DECISION ·
Ziihera + chemotherapy
zanidatamab-hrii with fluoropyrimidine and platinum chemotherapy · Jazz Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
First-line treatment for adults with unresectable locally advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma with HER2 IHC 3+ on an FDA-approved test.
LAMPGEN ANALYSIS
Why it matters
This regimen uses a narrower HER2 threshold than the tislelizumab combination. The FDA review attributed the progression-free survival effect primarily to the IHC 3+ subgroup.
What research teams should watch
Keep the IHC 3+ cutoff visible in order sets and eligibility review. When reporting the data, separate the chemotherapy-only combination arm from the tislelizumab-containing arm.
PRIMARY RECORDS